PharmaCyte Biotech, Inc. Q3 2026 Financial Report: Key Details for Investors
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) Releases Q3 2026 Financial Results
PharmaCyte Biotech, Inc. has released its unaudited financial statements for the quarterly period ended January 31, 2026. The following article highlights the critical points from the company’s SEC Form 10-Q filing, with a focus on essential updates for shareholders and potential price-sensitive information.
Key Highlights from Q3 2026 Financial Report
- Quarterly Reporting Period: Ended January 31, 2026.
- Exchange & Ticker: Common Stock, Par Value \$0.0001 per Share, listed on Nasdaq under the symbol PMCB.
- Outstanding Shares: 10,735,649 shares as of March 12, 2026.
- Filing Status: Non-accelerated filer; Smaller reporting company; Not an emerging growth company; Not a shell company.
- Number of Reportable Segments: 1 (indicating the company is focused on a single line of business).
Financial Position and Liquidity
| Key Metric |
As of Jan 31, 2026 |
As of Apr 30, 2025 |
| Cash and Cash Equivalents |
\$20,165,535 |
\$15,172,163 |
| Current Assets (including cash, receivables, etc.) |
Not explicitly stated |
\$22,375,238 |
| Convertible Note Receivable – Femasys (Current) |
\$0
(Previously \$3,696,000) |
\$3,696,000 |
Shareholders should note: The company’s cash and cash equivalents have increased significantly by approximately \$5 million since the last fiscal year-end. This demonstrates strong liquidity and prudent cash management, which is generally a positive sign for investors and may support future operations without immediate need for capital raises.
Disappearance of Femasys Note Receivable
A critical point for investors is the disappearance of the Convertible Note Receivable – Femasys from the asset side of the balance sheet, decreasing from \$3.7 million to \$0 over the reporting period. This could indicate a conversion, repayment, write-off, or some other transaction. The lack of this asset on the current balance sheet is material and could be price sensitive, depending on the specifics of the transaction and its impact on PharmaCyte’s cash flows or investment portfolio.
Company Compliance and Regulatory Status
- PharmaCyte Biotech has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 in the past 12 months and is current with its reporting obligations.
- The company has submitted all required interactive data files (XBRL) in compliance with Regulation S-T.
- It is not a large accelerated filer, not an accelerated filer, not an emerging growth company, and not a shell company, but is a smaller reporting company.
Potential Price Sensitive Information
- Significant Increase in Cash: The company’s cash position has increased by roughly \$5 million since the last fiscal year-end. This may reflect capital raises, investment conversions, or operational cash inflows. Investors should look for further disclosures on the source and intended use of these funds in Management’s Discussion and Analysis (MD&A).
- Loss of Convertible Note Receivable: The reduction in the Femasys note receivable to zero could materially affect the company’s asset base and potentially its income statement, depending on the nature of the transaction. This could be a positive (if converted to equity, repaid in cash, or sold at a gain) or a negative (if written off or impaired). Investors are advised to review the detailed notes and MD&A sections for clarification.
Other Information for Shareholders
- No evidence of defaults upon senior securities, unregistered sales of equity securities, or new legal proceedings during the quarter.
- The company has not indicated any material risk factors or mine safety disclosures specific to this quarter in the index.
- There is no indication of stock buybacks or other significant equity transactions impacting the outstanding share count, aside from the normal course of business.
Conclusion & Investor Takeaways
The Q3 2026 report from PharmaCyte Biotech, Inc. reflects a company with a strong liquidity position and continued compliance with SEC reporting requirements. The disappearance of the Femasys convertible note receivable is a noteworthy material development and warrants further investigation by shareholders, as its impact (positive or negative) could influence the company’s valuation and future prospects.
Investors should closely monitor upcoming disclosures, particularly in the MD&A and notes to the financial statements, for further details regarding the cash increase and the fate of the Femasys note. Any clarifications or subsequent events related to these items could move the share price.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings and consult with their licensed financial advisor before making any investment decisions. The author and publisher assume no responsibility or liability for any actions taken based on this summary.
View PharmaCyte Biotech, Inc. Historical chart here
